MKM Partners analyst Jon LeCroy said the consensus estimate for Amarin's (NASDAQ: AMRN) Vascepa launch seems attainable based on early ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE